Company intelligence / Profile preview

hema.to

Munich, Bavaria, Germanyhema.to ↗

Ownership: Private
Development stage: Commercial

Overview

hema.to’s AI software has demonstrated expert-level performance in differential diagnosis between common B-NHL types and healthy patients, with >99% mean accuracy on about 70% of cases in two clinical studies. The technology is CE-IVD compliant, FDA registered, and already deployed in leading hematology labs. Clinical results show improved sensitivity and specificity compared to conventional workflows[1].

Therapeutic areas: OncologyHematology
Modalities: Non-pharmacological therapy (AI-based clinical decision support software)
Industry: Digital Health Medical Devices

Partnerships

Institute for Hematopathology HamburgResult Laboratorium Dordrecht

Beyond the preview

Go deeper on hema.to.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on hema.to.

Explore the full profile